PCVX

Vaxcyte, Inc.

Price Chart

Latest Quote

$52.11

+0.67 (+1.30%)

Current Price

Previous Close	$51.44
Open	$51.71
Day High	$52.95
Day Low	$50.83
Volume	1,431,763

Fetched: 2026-06-22T23:22:12

Stock Information

Shares Outstanding	144.40M
Total Debt	$116.30M
Cash Equivalents	$1.74B
Net Income	$-946.53M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$7.52B
EPS (TTM)	$-6.89
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$5.81B
Income	$-946.53M
Book/sh	$20.76
Cash/sh	$12.03
Employees	507

Financial Ratios

Quick Ratio	7.18
Current Ratio	7.49
Debt/Eq	3.88

Returns & Margins

ROA	-20.23%
ROE	-30.55%

Ownership

Insider Ownership	0.53%
Institutional Ownership	114.63%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-7.02
P/B	2.51

Analyst Data

Recommendation	strong_buy
Target Price	$109.00

Technical Indicators

SMA20	$48.84
SMA50	$53.53
SMA200	$49.15
RSI	60.36
ATR	2.1603

Shares Float	131.96M
Short Float	10.08%
Short Ratio	8.41
Volatility	1.24
Rel Volume	1.00

Performance History

Week	+9.80%
Month	+10.47%
Quarter	-4.77%
6 Months	+21.02%
YTD	+12.16%
Year	+56.02%
3 Years	-0.55%
5 Years	+126.86%
10 Years	+99.27%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-22	$52.11	1,431,763
2026-06-18	$51.44	2,837,000
2026-06-17	$50.67	1,117,600
2026-06-16	$49.31	1,003,800
2026-06-15	$49.56	1,739,400
2026-06-12	$47.46	1,031,000
2026-06-11	$47.29	2,039,000
2026-06-10	$45.42	1,079,600
2026-06-09	$46.88	1,318,800
2026-06-08	$46.33	1,341,200
2026-06-05	$47.36	1,106,300
2026-06-04	$48.76	1,232,800
2026-06-03	$46.93	1,508,800
2026-06-02	$47.41	1,495,400
2026-06-01	$48.91	1,360,100
2026-05-29	$51.40	1,414,000
2026-05-28	$51.06	1,384,800
2026-05-27	$51.02	1,413,900
2026-05-26	$50.11	1,318,200

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

📰 Latest News

Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine

Insider Monkey • 2026-06-22T14:14:04Z

Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study

Insider Monkey • 2026-06-17T15:55:36Z

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Motley Fool • 2026-06-03T14:04:22Z

Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments

Simply Wall St. • 2026-06-01T06:12:11Z

Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials

Insider Monkey • 2026-05-29T06:40:08Z

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

Motley Fool • 2026-05-24T14:39:48Z

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

Motley Fool • 2026-05-24T14:33:59Z

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise

Investor's Business Daily • 2026-05-20T20:10:12Z

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Motley Fool • 2026-05-19T17:37:19Z

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Motley Fool • 2026-05-19T17:26:23Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$923,675,000	$569,546,000	$393,041,000	$209,261,000
Other Income Expense	$37,329,000	$-4,375,000	$-72,132,000	$-22,578,000
Other Non Operating Income Expenses	$37,329,000	$-4,375,000	$2,868,000	$417,000
Net Non Operating Interest Income Expense	$119,718,000	$109,994,000	$62,907,000	$8,354,000
Operating Expense	$923,675,000	$569,546,000	$393,041,000	$209,261,000
General And Administrative Expense	$129,369,000	$92,902,000	$60,700,000	$39,810,000
Interest Expense	-	$0	$0	$2,000
Interest Expense Non Operating	-	$0	$0	$2,000
Other Operating Expenses	-	-	$-4,765,000	$-1,931,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Net Interest Income	$119,718,000	$109,994,000	$62,907,000	$8,354,000
Interest Income	$119,718,000	$109,994,000	$62,907,000	$8,356,000
Normalized Income	$-766,628,000	$-463,927,000	$-327,266,000	$-200,490,000
Net Income From Continuing And Discontinued Operation	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Total Operating Income As Reported	$-923,675,000	$-569,546,000	$-468,041,000	$-232,256,000
Net Income Common Stockholders	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Net Income	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Net Income Including Noncontrolling Interests	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Net Income Continuous Operations	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Pretax Income	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Special Income Charges	$0	$0	$-75,000,000	$-22,995,000
Interest Income Non Operating	$119,718,000	$109,994,000	$62,907,000	$8,356,000
Operating Income	$-923,675,000	$-569,546,000	$-393,041,000	$-209,261,000
Per Share
Diluted EPS	$-5.63	$-3.80	$-4.14	$-3.44
Basic EPS	$-5.63	$-3.80	$-4.14	$-3.44
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-898,815,000	$-553,701,000	$-307,870,000	$-191,035,000
Total Unusual Items	$0	$0	$-75,000,000	$-22,995,000
Total Unusual Items Excluding Goodwill	$0	$0	$-75,000,000	$-22,995,000
Reconciled Depreciation	$24,860,000	$15,845,000	$10,171,000	$9,453,000
EBITDA (Bullshit earnings)	$-898,815,000	$-553,701,000	$-382,870,000	$-214,030,000
EBIT	$-923,675,000	$-569,546,000	$-393,041,000	$-223,483,000
Diluted Average Shares	$136,089,506	$121,997,348	$97,157,690	$64,877,988
Basic Average Shares	$136,089,506	$121,997,348	$97,157,690	$64,877,988
Diluted NI Availto Com Stockholders	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Restructuring And Mergern Acquisition	$0	$0	$75,000,000	$22,995,000
Research And Development	$794,306,000	$476,644,000	$332,341,000	$169,451,000
Selling General And Administration	$129,369,000	$92,902,000	$60,700,000	$39,810,000
Other Gand A	$129,369,000	$92,902,000	$60,700,000	$39,810,000
Gain On Sale Of Ppe	-	-	$0	$-44,000
Gain On Sale Of Security	-	-	$-1,897,000	$-1,470,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$2,685,510,000	$3,305,819,000	$1,240,468,000	$953,613,000
Total Assets	$3,002,717,000	$3,511,318,000	$1,407,917,000	$1,006,178,000
Total Non Current Assets	$1,375,356,000	$1,723,333,000	$311,963,000	$63,623,000
Other Non Current Assets	$1,974,000	$3,199,000	$3,977,000	$1,065,000
Investmentin Financial Assets	$881,664,000	$1,387,510,000	$162,675,000	-
Current Assets	$1,627,361,000	$1,787,985,000	$1,095,954,000	$942,555,000
Other Current Assets	$66,402,000	$40,777,000	$15,727,000	$11,179,000
Cash Cash Equivalents And Short Term Investments	$1,560,959,000	$1,747,208,000	$1,080,227,000	$931,376,000
Cash And Cash Equivalents	$173,959,000	$387,878,000	$397,451,000	$834,657,000
Cash Equivalents	$88,542,000	$327,347,000	$347,448,000	$778,459,000
Cash Financial	$85,417,000	$60,531,000	$50,003,000	$56,198,000
Non Current Prepaid Assets	-	-	$2,768,000	$4,361,000
Prepaid Assets	-	-	-	$11,179,000
Debt
Total Debt	$117,481,000	$71,110,000	$29,224,000	$17,941,000
Long Term Debt And Capital Lease Obligation	$111,357,000	$65,219,000	$22,111,000	$12,031,000
Current Debt And Capital Lease Obligation	$6,124,000	$5,891,000	$7,113,000	$5,910,000
Liabilities
Total Liabilities Net Minority Interest	$317,207,000	$205,499,000	$167,449,000	$52,565,000
Total Non Current Liabilities Net Minority Interest	$111,457,000	$65,319,000	$22,111,000	$12,040,000
Other Non Current Liabilities	$100,000	$100,000	-	$9,000
Current Liabilities	$205,750,000	$140,180,000	$145,338,000	$40,525,000
Payables And Accrued Expenses	$176,626,000	$113,734,000	$127,169,000	$33,435,000
Payables	$75,610,000	$48,554,000	$14,587,000	$9,795,000
Total Tax Payable	$4,706,000	$102,000	-	-
Accounts Payable	$70,904,000	$48,452,000	$14,587,000	$9,795,000
Non Current Deferred Liabilities	-	-	-	-
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$2,685,510,000	$3,305,819,000	$1,240,468,000	$953,613,000
Total Equity Gross Minority Interest	$2,685,510,000	$3,305,819,000	$1,240,468,000	$953,613,000
Stockholders Equity	$2,685,510,000	$3,305,819,000	$1,240,468,000	$953,613,000
Gains Losses Not Affecting Retained Earnings	$1,587,000	$-3,873,000	$179,000	$-361,000
Other Equity Adjustments	$1,587,000	$-3,873,000	$179,000	$-361,000
Retained Earnings	$-2,154,947,000	$-1,388,319,000	$-924,392,000	$-522,126,000
Other
Ordinary Shares Number	$131,058,858	$124,893,034	$95,364,831	$79,470,670
Share Issued	$131,058,858	$124,893,034	$95,364,831	$79,470,670
Tangible Book Value	$2,685,510,000	$3,305,819,000	$1,240,468,000	$953,613,000
Invested Capital	$2,685,510,000	$3,305,819,000	$1,240,468,000	$953,613,000
Working Capital	$1,421,611,000	$1,647,805,000	$950,616,000	$902,030,000
Capital Lease Obligations	$117,481,000	$71,110,000	$29,224,000	$17,941,000
Total Capitalization	$2,685,510,000	$3,305,819,000	$1,240,468,000	$953,613,000
Additional Paid In Capital	$4,838,736,000	$4,697,883,000	$2,164,583,000	$1,476,018,000
Capital Stock	$134,000	$128,000	$98,000	$82,000
Common Stock	$134,000	$128,000	$98,000	$82,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$111,357,000	$65,219,000	$22,111,000	$12,031,000
Current Capital Lease Obligation	$6,124,000	$5,891,000	$7,113,000	$5,910,000
Pensionand Other Post Retirement Benefit Plans Current	$23,000,000	$20,555,000	$11,056,000	$1,180,000
Current Accrued Expenses	$101,016,000	$65,180,000	$112,582,000	$23,640,000
Investments And Advances	$881,664,000	$1,387,510,000	$162,675,000	$26,549,000
Available For Sale Securities	$881,664,000	$1,387,510,000	$162,675,000	-
Net PPE	$491,718,000	$332,624,000	$145,311,000	$31,648,000
Accumulated Depreciation	$-32,770,000	$-16,274,000	$-9,272,000	$-6,117,000
Gross PPE	$524,488,000	$348,898,000	$154,583,000	$37,765,000
Leases	$7,239,000	$4,384,000	$1,460,000	$1,353,000
Other Properties	$178,555,000	$127,643,000	$64,241,000	$34,388,000
Machinery Furniture Equipment	$338,694,000	$216,871,000	$88,882,000	$2,024,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$1,387,000,000	$1,359,330,000	$682,776,000	$96,719,000
Construction In Progress	-	-	-	-

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-712,550,000	$-571,786,000	$-364,667,000	$-176,438,000
Operating Activities
Operating Cash Flow	$-655,577,000	$-452,627,000	$-296,790,000	$-170,597,000
Cash Flow From Continuing Operating Activities	$-655,577,000	$-452,627,000	$-296,790,000	$-170,597,000
Operating Gains Losses	$-34,768,000	$4,232,000	-	$44,000
Investing Activities
Capital Expenditure	$-56,973,000	$-119,159,000	$-67,877,000	$-5,841,000
Investing Cash Flow	$437,354,000	$-2,005,666,000	$-773,311,000	$74,585,000
Cash Flow From Continuing Investing Activities	$437,354,000	$-2,005,666,000	$-773,311,000	$74,585,000
Financing Activities
Issuance Of Capital Stock	$0	$2,435,656,000	$636,043,000	$856,480,000
Financing Cash Flow	$2,014,000	$2,448,508,000	$639,813,000	$861,547,000
Cash Flow From Continuing Financing Activities	$2,014,000	$2,448,508,000	$639,813,000	$861,547,000
Net Other Financing Charges	$-10,991,000	$-14,292,000	$-3,876,000	$-861,000
Net Common Stock Issuance	$0	$2,435,656,000	$636,043,000	$856,480,000
Common Stock Issuance	$0	$2,435,656,000	$636,043,000	$856,480,000
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
End Cash Position	$175,425,000	$389,195,000	$398,554,000	$835,528,000
Beginning Cash Position	$389,195,000	$398,554,000	$835,528,000	$69,856,000
Effect Of Exchange Rate Changes	$2,439,000	$426,000	$-6,686,000	$137,000
Changes In Cash	$-216,209,000	$-9,785,000	$-430,288,000	$765,535,000
Proceeds From Stock Option Exercised	$13,005,000	$27,144,000	$7,646,000	$5,928,000
Net Investment Purchase And Sale	$494,327,000	$-1,886,507,000	$-705,434,000	$80,426,000
Sale Of Investment	$1,705,826,000	$1,200,194,000	$624,462,000	$183,171,000
Purchase Of Investment	$-1,211,499,000	$-3,086,701,000	$-1,329,896,000	$-102,745,000
Net PPE Purchase And Sale	$-56,973,000	$-119,159,000	$-67,877,000	$-5,841,000
Purchase Of PPE	$-56,973,000	$-119,159,000	$-67,877,000	$-5,841,000
Change In Working Capital	$-3,452,000	$-54,895,000	$81,320,000	$12,737,000
Change In Other Working Capital	$2,302,000	$9,517,000	$9,876,000	$-2,275,000
Change In Other Current Liabilities	$46,371,000	$41,886,000	$11,284,000	$1,151,000
Change In Other Current Assets	$-92,257,000	$-76,459,000	$-49,731,000	$-465,000
Change In Payables And Accrued Expense	$56,932,000	$-24,012,000	$92,021,000	$13,893,000
Change In Accrued Expense	$37,026,000	$-58,596,000	$80,796,000	$10,997,000
Change In Payable	$19,906,000	$34,584,000	$11,225,000	$2,896,000
Change In Account Payable	$19,906,000	$34,584,000	$11,225,000	$2,896,000
Change In Prepaid Assets	$-16,800,000	$-5,827,000	$17,870,000	$433,000
Other Non Cash Items	$-14,434,000	$-38,704,000	$-34,775,000	$7,048,000
Stock Based Compensation	$138,845,000	$84,822,000	$48,760,000	$23,650,000
Depreciation Amortization Depletion	$24,860,000	$15,845,000	$10,171,000	$9,453,000
Depreciation And Amortization	$24,860,000	$15,845,000	$10,171,000	$9,453,000
Depreciation	$24,860,000	$15,845,000	$10,171,000	$9,453,000
Net Foreign Currency Exchange Gain Loss	$-34,768,000	$4,232,000	$0	$0
Net Income From Continuing Operations	$-766,628,000	$-463,927,000	$-402,266,000	$-223,485,000
Interest Paid Supplemental Data	-	-	$0	$2,000
Sale Of PPE	-	-	$0	$7,000
Asset Impairment Charge	-	-	$0	$213,000
Amortization Of Securities	-	-	$-34,775,000	$-947,000
Repayment Of Debt	-	-	-	$0
Net Issuance Payments Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0

Fetched: 2026-06-17